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On a worldwide basis, gastric cancer is a
major cancer-related killer. In Japan and
certain other Asian countries gastric can-
cer tops the list of cancer-induced deaths.
While clear links have been discovered
between environmental factors, such as
Helicobacter pylori infection, dietary com-
ponents, and gastric cancer frequencies,
the genetic basis for gastric cancer devel-
opment is still largely unclear. In the April
5 issue of Cell, Li and coworkers (2002)
describe the uncovering of RUNX3/
AML2/CBFA3/PEBP2αC as a candidate
tumor suppressor in gastric cancer devel-
opment. RUNX3 belongs to the Runt
domain family of transcription factors,
which consists of 3 DNA binding α sub-
units, RUNX1, RUNX2, and RUNX3 (see
Table 1 for alternative names), each of
which is capable of forming heterodimers
with the common β subunit CBFβ. RUNX
heterodimers are relatively weakly acting
transcriptional regulators, the potency of
which can be induced by associations
with transcriptional (co)activators, such
as MYB, ETS, and p300/CBP, or co-
repressors such as TLE1 and mSin3A
(Perry et al., 2002). The main family fea-
ture, the 128 amino acid runt domain
named for its high homology to the
Drosophila pair-rule protein runt, facili-
tates dimerization and DNA binding. Like
their counterparts in D. melanogaster
and C. elegans, mammalian RUNX fami-
ly transcription factors play important
roles in cell fate determination during
development.
The work of Li and coworkers
(2002) completes the mouse knockout
analyses of the Runx family and under-
scores the role of Runt family members
as cancer-related genes. As previously
found for Runx1 (Okuda et al., 1996),
Runx2 (Otto et al., 1997), and Cfbβ
(Wang et al., 1996), genetic ablation of
Runx3 has profound effects. While
Runx3 knockout mice are born in
Mendelian ratios, they die soon after
birth probably due to starvation. Runx3
is strongly expressed in gastrointestinal
organs in the developing embryo and
throughout adult life of the mouse and
the gastric epithelium in Runx3 knock-
outs displays hyperplasia and a reduced
apoptotic rate. Interestingly, when ana-
lyzed in primary cultures Runx3−/− gastric
epithelial cells are less sensitive to TGF-
β-mediated growth inhibition, based on a
marked failure to enter apoptosis when
treated with TGF-β. To investigate the
potential connection between RUNX3
and gastric cancers in humans, Li et al.
(2002) analyze a series of gastric cancer
cell lines and primary human gastric
tumors. Out of 46 primary human
tumors, 30% displayed hemizygosity of
RUNX3 with a significant correlation
between RUNX3 loss and gastric cancer
progression stage. Furthermore, RUNX3
expression analysis revealed that on
average 60% of the analyzed primary
human gastric tumors exhibited reduced
RUNX3 levels rising to nearly 90%
among the late stage, representing high-
ly metastatic tumors. Upon examination
of 119 tumor samples, Li et al. were able
to identify only a single nucleotide transi-
tion causing an arginine-to-cytosine con-
version within the conserved Runt
domain, which did not strengthen the
tumor suppressor argument much.
However, the high CpG nucleotide con-
tent triggered analysis of DNA methyla-
tion status, and interestingly RUNX3
hypermethylation in a large number of
primary tumor samples was found to cor-
relate with gene silencing, which indi-
cates an unusual strong prevalence for
epigenetic gene silencing. To further
establish a causal link between RUNX3
expression and oncogenesis, Li et al.
injected gastric cancer cells engineered
to overexpress either wild-type or Runt
domain mutated RUNX3 into nude mice.
While RUNX3 mediated a significant
reduction in tumorigenicity, the Runt
domain mutant aggravated tumor forma-
tion. Moreover, gastric epithelial cells
immortalized by loss of p53 only were
able to form tumors in nude mice when
Runx3 was also deleted. Together, these
results underline the role of RUNX3 as a
bona fide tumor suppressor.
It is now clear that all three Runx
family members play important roles in
normal developmental processes as
well as in cancers (Table 1). RUNX1,
perhaps better known as AML1, plays a
critical role in hematopoietic develop-
ment, and genetic ablation of either
Runx1 or Cbfβ results in embryonic
RUNX: A trilogy of cancer genes
The RUNX family of transcription factors plays pivotal roles during normal development and in neoplasias. Recent data
involve RUNX3 as an important tumor suppressor in gastric cancers and pose interesting questions about how perturbed
levels and interspecific competition among RUNX family members may contribute to tumorigenesis.
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lethality and a complete lack of fetal liver
hematopoiesis (Okuda et al., 1996;
Wang et al., 1996). RUNX1 has long
been recognized as an important
translocation breakpoint in human
leukemias, with the TEL-AML1 t(12;21)
fusion accounting for 20% of acute lym-
phoblastic leukemia (ALL) cases and
the AML1-ETO t(8;21) fusion accounting
for 12% of acute myeloid leukemias
(AML) (Look, 1997). Importantly, a num-
ber of the translocation breakpoint
products involving RUNX1 have been
shown to have trans-dominant effects
and block the normal functions of the
RUNX1/CBFB heterodimer (reviewed in
Perry et al., 2002).The hypothetical func-
tion of RUNX1 as a tumor suppressor for
AML was further strengthened by the
finding that familial mutations with
RUNX1 cause thrombocytopenia and
predispose to acute myeloid leukemia
(Song et al., 1999). The Runx2 gene
product is pivotal for osteoblast differenti-
ation and bone ossification (Otto et al.,
1997). Furthermore, RUNX2 is haploin-
sufficient, and heterozygous RUNX2
loss of function gives rise to cleidocranial
dysplasia in both humans and mice, a
disorder characterized by multiple skele-
tal abnormalities (Otto et al., 1997;
Mundlos et al., 1997). The oncogenic
properties of Runx2 were demonstrated
in transgenic mice where Runx2 overex-
pression pertubates T cell development
and synergizes strongly with c-myc in
lymphomagenesis (Vaillant et al., 1999).
Interestingly, all three Runx family mem-
bers have been identified as putative
proto-oncogenes in mouse insertional
mutagenesis leukemia models (Li et al.,
1999; Stewart et al., 1997; A.H.L. and
M.v.L., submitted), hence further indicat-
ing that absolute levels of the Runx het-
erodimers are important and need to be
tightly controlled.
How can we seek to understand the
apparently opposing effects of RUNX
family members as, on the one hand
dominant-acting oncogenes, while on
the other hand being important tumor
suppressors? One possible explanation
could be that since all three RUNX het-
erodimers are known to recognize the
same consensus DNA core motif
(TGt/cGGT), erroneous expression of
RUNX members outside of their normal
tissues might exert oncogenic effects
through competitive interference with the
RUNX heterodimer species normally
present within that particular tissue. Also,
RUNX members differ in their associa-
tions with coacting factors; RUNX3 for
instance entirely lacks a domain present
in RUNX1 and RUNX2 responsible for
interaction with Ets family members (Bae
et al., 1995). Along the same lines, the
“wiring” of RUNX members, in terms of
activating and repressing signaling path-
ways, may differ in different cells types. It
will be of obvious importance to use
expression profiling and other tech-
niques to find the relevant downstream
targets for each of the Runx het-
erodimeric transcription factors.
The recognition of Helicobacter pylori
as a major causative agent in gastric can-
cer development has led to the classifica-
tion of H. pylori as a Class I carcinogen by
the World Health Organization. H. pylori
infection causes release of reactive oxy-
gen species, mitogenic stimulation, and
constitutive inflammatory response in
gastric epithelium (Peek and Blaser,
2002; Karin et al., 2002). Early steps in
gastric neoplasias involve transition of
normal epithelial mucosa to gastritis, a
condition promoted by H. pylori, implicat-
ing H. pylori in tumor initiation and pro-
motion (Peek and Blaser, 2002). Later
stages involve many of the “common
themes” in tumorigenesis: p53 loss of
function, K-ras activation, and E-cad-
herin loss or mutation (Kuniyasu et al.,
2000). So where does RUNX3 fit into the
picture? On the one hand, Runx3 loss
may be an early event, as is suggested
by the hyperplasia in the Runx knockout
mice; on the other hand, the finding of Li
and coworkers (2002) that RUNX3 loss
increases with cancer progression sug-
gests a role in tumor progression. This
dual action of Runx loss may be
explained by its effects on inducing both
cell proliferation (inducing hyperplasia)
and on preventing apoptosis (which
could be selected for in tumor progres-
sion). Indeed, a role for RUNX3 in
proapoptotic pathways is sustained by
the fact that Runx3−/− gastric epithelial
cells display apoptotic defects in
response to TGF-β. In support of a role
for RUNX family members in TGF-β and
bone morphogenic protein signaling
pathways are the findings that all three
RUNX members have been found to bind
R-Smads (Hanai et al., 1999) and that
thymocytes from Runx2 transgenic mice
are hypersensitive to TGF-β (Vaillant et
al., 1999).
Interestingly, Runx3 loss appears
specifically to predispose to gastric can-
cer but not to colon cancer, despite
equally high expression of Runx3 in both
gastric and colonic epithelial cells.
Among several other speculative expla-
nations, one is that this could relate to
the unique milieu and cofactors in the
stomach, such as low pH, dietary factors
and H. pylori. Given the capability of both
H. pylori and loss of Runx3 to induce ini-
tial lesions and hyperplasia, an intriguing
possibility could be that Runx3 is one of
the downstream “targets” of H. pylori
action. Having the Runx3 knockout mice
in hand, this and several other important
questions can now be investigated
directly. While the early death of Runx3−/−
mice precludes tumorigenesis experi-
ments, careful monitoring of Runx3+/−
mice, perhaps in combination with other
Table 1. Functions and oncogenesis of Runt-related transcription factorsa
Gene Alternative Proposed essential Mouse (−/−) phenotype Tumorigenesis
gene names function
RUNX1 AML1/CBFA2/ Definitive Embryonic lethal. Absence Hemizygocity in humans predisposes to acute
PEBP2αB hematopoiesis of fetal liver hematopoiesis. myeloid leukemia. Frequent translocation
breakpoint. Common insertion site in retrovirus-
induced mouse leukemia.
RUNX2 AML3/CBFA1/ Bone ossification Dies at birth from Transgenic Runx2 overexpression predisposes to
PEBP2αA respiratory failure. T-cell lymphomas. Common insertion site in
retrovirus-induced mouse leukemia.
RUNX3 AML2/CBFA3/ Development of the Dies soon after birth. Frequently inactivated in human gastric cancers.
PEBP2αC gastrointestinal tract Hyperplastic gastric epithelium. Common insertion site in retrovirus-induced mouse
leukemia.
aSee text for references
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genetic lesions such as p53 ablation, is
expected to reveal gastric cancer pre-
disposition and could provide more
detailed insight into the roles of Runx3 in
tumor initiation and progression and 
its possible interactions with cofactors.
Alternatively, a conditional Runx3 knock-
out mouse may serve this purpose. In
addition, such mouse models will allow
investigation of the extent to which loss
of RUNX3 complements or substitutes
for other lesions known from gastric can-
cers, such as E-cadherin loss, RAS
mutations, and loss of DCC. It can be
expected that this mouse model for gas-
tric cancer will greatly assist unraveling
of the underlying molecular causes for
this important widespread disease in the
coming years.
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The secrets of selective estrogen receptor modulation:
Cell-specific coregulation
A specific increase in the level of a single coactivator appears to enhance estrogen action with tamoxifen at some gene 
targets in uterine cells but not breast cells.
The discovery and development of antie-
strogens as treatments for estrogen
receptor (ER) positive breast cancer
(Lerner and Jordan, 1990) introduced a
new approach for targeted therapy with
few side effects compared to traditional
cytotoxic chemotherapy. The novel so-
called nonsteroidal antiestrogens, initial-
ly investigated during the 1960s, were all
classified as partial estrogen agonists in
the rat uterus but with a predominantly
antiestrogen action. This pharmacologic
activity in the laboratory extrapolated to
antitumor action by blocking estrogen-
stimulated breast tumor growth at the
ER. Tamoxifen was introduced clinically
during the 1970s, and the drug has had a
profound effect on patient survival. It is
estimated that 400,000 women are alive
today because of the success of tamox-
ifen treatment. However, tamoxifen is a
pioneering medicine over and above its
ability to save lives.
The recognition of selective estrogen
receptor modulation in the laboratory
during the 1980s (Jordan, 2001) has had
important implications not only for the
evaluation of the side effects associated
with tamoxifen, but also has established
the rationale for a new class of drugs, the
selective estrogen receptor modulators
(SERMs). It is now clear that SERMs
have potential as multifunctional medi-
cines. The SERMs express estrogen-like
actions in bone, lower circulating choles-
terol, but produce an antiestrogenic
action in the breast. The actions of
tamoxifen in the endometrium are impor-
tant because they illustrate the concept
of selective ER modulation. When both
breast and endometrial tumors are
implanted into immune deficient mice
(Gottardis et al., 1988), tamoxifen
enhances the growth of endometrial can-
cer but prevents the growth of breast
cancer. The tamoxifen ER complex is
perceived as an estrogen in endometrial
cancer cells but as an antiestrogen in
breast cancer. This concept translated to
the clinic with a predicted modest rise in
the incidence of endometrial cancer in
postmenopausal women during tamox-
ifen therapy. The question is, how is the
pharmacology of tamoxifen reversed in
